Latest Information Update: 02 Jan 2017
At a glance
- Originator AbbVie
- Class Antineoplastics
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 28 Dec 2016 AbbVie plans a phase I trial in Solid tumours in USA (NCT02988960)
- 08 Dec 2016 Preclinical trials in Solid tumours in USA (IV)